Mesenchymal Stem Cell Infusion
IIT2025028
Phase 1 mab active
Quick answer
Mesenchymal Stem Cell Infusion for Immune Effector Cell Associated Hematotoxicity is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Immune Effector Cell Associated Hematotoxicity
- Phase
- Phase 1
- Modality
- mab
- Status
- active